Comprehensive biomarker analyses and updated results of PURE-01 study: Neoadjuvant pembrolizumab (pembro) in muscle-invasive urothelial bladder carcinoma (MIBC)
Published date:
10/01/2018
Excerpt:
Pembro is given 200mg q3w x3 cycles. Pathologic complete response (pT0) in ITT population is the primary endpoint (EP)….8/8 pts (100%) with DDR/RB1 GA and CPS≥21% achieved pT0.